title: Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation.
abstract: A total of 31 patients with gastric cancer showing peritoneal dissemination received continuous hyperthermic peritoneal perfusion (CHPP) in combination with the administration of cisplatin (CDDP) and mitomycin C (MMC). The authors developed a new special device named the peritoneal cavity expander (PCE) for sufficient perfusion and direct temperature measurement in the peritoneal cavity. As complications of CHPP three patients presented with bone marrow suppressions (leukocytes less than or equal to 3000/mm3 and/or platelets less than or equal to 30,000/mm3): one, leakage of intestinal anastomosis; one, intestinal perforation; and one, acute renal failure. But none of them was lethal. Twelve of 31 patients who had received CHPP during the initial operation underwent second-look operation (SLO) for the assessing the effects of CHPP and for resecting residual or recurrent tumors. Among 12 patients who received SLO complete response (CR) was observed in four patients, partial response (PR) in one, no change (NC) in three, and progressive disease (PD) in four, with the overall response rates (%CR + %PR) standing at 41%. Two-year survival rate of the complete and partial responders was 50%, which was significantly higher than 0% of the other responders (NC + PD). The survival curves of the two groups were significantly different (P less than 0.05, generalized Wilcoxon test). These results supported that CHPP was well tolerated and effective for the treatment of patients with peritoneal dissemination in gastric cancer when combined with anti-cancer drugs having synergism with hyperthermia. Since the outcome of SLO was one of prognostic factors it was important to follow up these patients by SLO.
authors.affiliation: Second Department of Surgery, School of Medicine, Kanazawa University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Fujimura
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: S
authors.initials: S
authors.lastname: Fushida
authors.forename: M
authors.initials: M
authors.lastname: Urade
authors.forename: S
authors.initials: S
authors.lastname: Takegawa
authors.forename: T
authors.initials: T
authors.lastname: Kamata
authors.forename: K
authors.initials: K
authors.lastname: Sugiyama
authors.forename: H
authors.initials: H
authors.lastname: Hasegawa
authors.forename: K
authors.initials: K
authors.lastname: Katayama
authors.forename: K
authors.initials: K
authors.lastname: Miwa
mesh_terms: D000328:Adult; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007668:Kidney / Q000187:drug effects; D007813:Laparotomy; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D010477:Perfusion; D010534:Peritoneal Neoplasms / Q000628:therapy*; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D007507:Therapeutic Irrigation
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D002945:Cisplatin